Centre de Recherche du CHU Sainte-Justine, University of Montreal, Montreal (Kumar, Harvey, Huguet, Jean-Louis, Douard, Martin, Younis, Tamer, Dumas, Jacquemont); Mila-Quebec AI Institute, University of Montreal, Montreal (Dumas); Laboratoire de Recherche en Neuroimagerie, Department of Clinical Neurosciences (Modenato, Martin-Brevet, Lippé, Draganski), and Service des Troubles du Spectre de l'Autisme et Apparentés (Maillard, Rodriguez-Herreros, Pain), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; Human Genetics and Cognitive Functions, Institut Pasteur, and Université de Paris, CNRS UMR 3571, Paris (Moreau); Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles (Kushan, Bearden); School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands (Silva, Linden); Centre for Neuropsychiatric Genetics and Genomics (Silva, van den Bree, Owen, Hall), Division of Psychological Medicine and Clinical Neurosciences, School of Medicine (van den Bree, Owen, Hall), and Neuroscience and Mental Health Innovation Institute (van den Bree, Linden, Hall), Cardiff University, Cardiff, U.K.; Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Draganski); Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey (Ching, Moreau, Thompson); Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia (Schultz, Almasy); Lifespan Brain Institute, Children's Hospital of Philadelphia and Penn Medicine, Philadelphia (Schultz, Almasy); Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Almasy); Department of Psychiatry, Harvard Medical School, Boston, and Tommy Fuss Center for Neuropsychiatric Disease Research, Boston Children's Hospital, Boston (Glahn); Department of Biomedical Engineering, Duke University, Durham, N.C. (Isaev); Department of Biomedical Engineering, Oregon Health and Science University, Portland (Ragothaman); Department of Psychology, Georgia State University, Atlanta (Turner); Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago (Alpert, Wang); Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center, Columbus (Wang); Department of Psychiatry and Behavioral Sciences and Department of Psychology, Stanford University, Stanford (Ho); Orygen, National Centre of Excellence in Youth Mental Health, Parkville, Australia, and Centre for Youth Mental Health, University of Melbourne, Melbourne (Schmaal); NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, and University of Oslo, Oslo (Sønderby, Andreassen); Department of Medical Genetics, Oslo University Hospital, Oslo (Sønderby); K.G. Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo (Sønderby, Andreassen); Department of Biomedical Engineering, Illinois Institute of Technology, Chicago (Gutman).
Am J Psychiatry. 2023 Sep 1;180(9):685-698. doi: 10.1176/appi.ajp.20220304. Epub 2023 Jul 12.
Copy number variants (CNVs) are well-known genetic pleiotropic risk factors for multiple neurodevelopmental and psychiatric disorders (NPDs), including autism (ASD) and schizophrenia. Little is known about how different CNVs conferring risk for the same condition may affect subcortical brain structures and how these alterations relate to the level of disease risk conferred by CNVs. To fill this gap, the authors investigated gross volume, vertex-level thickness, and surface maps of subcortical structures in 11 CNVs and six NPDs.
Subcortical structures were characterized using harmonized ENIGMA protocols in 675 CNV carriers (CNVs at 1q21.1, TAR, 13q12.12, 15q11.2, 16p11.2, 16p13.11, and 22q11.2; age range, 6-80 years; 340 males) and 782 control subjects (age range, 6-80 years; 387 males) as well as ENIGMA summary statistics for ASD, schizophrenia, attention deficit hyperactivity disorder, obsessive-compulsive disorder, bipolar disorder, and major depression.
All CNVs showed alterations in at least one subcortical measure. Each structure was affected by at least two CNVs, and the hippocampus and amygdala were affected by five. Shape analyses detected subregional alterations that were averaged out in volume analyses. A common latent dimension was identified, characterized by opposing effects on the hippocampus/amygdala and putamen/pallidum, across CNVs and across NPDs. Effect sizes of CNVs on subcortical volume, thickness, and local surface area were correlated with their previously reported effect sizes on cognition and risk for ASD and schizophrenia.
The findings demonstrate that subcortical alterations associated with CNVs show varying levels of similarities with those associated with neuropsychiatric conditions, as well distinct effects, with some CNVs clustering with adult-onset conditions and others with ASD. These findings provide insight into the long-standing questions of why CNVs at different genomic loci increase the risk for the same NPD and why a single CNV increases the risk for a diverse set of NPDs.
拷贝数变异(CNVs)是多种神经发育和精神疾病(NPDs)的已知遗传多效风险因素,包括自闭症(ASD)和精神分裂症。目前尚不清楚同一疾病的不同 CNV 如何影响皮质下脑结构,以及这些改变与 CNV 赋予疾病风险的程度有何关系。为了填补这一空白,作者研究了 11 个 CNV 和 6 个 NPD 中的皮质下结构的总体积、顶点厚度和表面图谱。
使用 ENIGMA 协议,对 675 名 CNV 携带者(1q21.1、TAR、13q12.12、15q11.2、16p11.2、16p13.11 和 22q11.2 的 CNV;年龄范围 6-80 岁;340 名男性)和 782 名对照者(年龄范围 6-80 岁;387 名男性)的皮质下结构进行了特征描述,并使用 ASD、精神分裂症、注意缺陷多动障碍、强迫症、双相情感障碍和重度抑郁症的 ENIGMA 汇总统计数据。
所有 CNV 均在至少一项皮质下测量中发生改变。每个结构都受到至少两个 CNV 的影响,而海马体和杏仁核受到五个 CNV 的影响。形态分析检测到体积分析中平均化的亚区改变。在 CNV 和 NPD 中,确定了一个共同的潜在维度,其特征是对海马体/杏仁核和纹状体/苍白球的影响相反。CNV 对皮质下体积、厚度和局部表面积的影响与它们先前报道的对认知以及 ASD 和精神分裂症风险的影响相关。
这些发现表明,与 CNV 相关的皮质下改变与与神经精神疾病相关的改变表现出不同程度的相似性,以及明显的影响,一些 CNV 与成人发病的疾病聚类,而另一些则与 ASD 聚类。这些发现为长期存在的问题提供了一些见解,即为什么不同基因组位置的 CNV 会增加同一种 NPD 的风险,以及为什么单个 CNV 会增加一系列不同的 NPD 的风险。